Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2016-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gammagard Liquid and rHuPH20 in PID
NCT00814320
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
NCT02503293
Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
NCT01814800
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
NCT04985760
Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
NCT00073216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
30 subjects will receive Gadolinium subcutaneously, and 30 subjects will receive Gadolinium subdermally with ASIS device. An MRI will be taken promptly after Gadolinium injection, as starting reference, to which subsequent MRI taken at 6 hrs, 12 hrs, and 24 hrs later will be compared for Persistent %. Since there isn't a way to measure level of Gadolinium within it, or any other (e.g.
GAMMAGARD) for that matter, at least the Prolongation of Gadolinium may be approximated by the greater or longer Persistent % on MRI. However, this approximation can only work if the variables are minimized to the same population with Primary Immunodeficiency (PI), and the particular skin affected by it. Case in point, Primary Immunodeficiency (PI) patients are prone to infection, and tend to have scared skin with less vascularity, so expectantly will have prolonged Gadolinium subcutaneously Persistent %, which will be very different from the skin of normal patients, while the Gadolinium subdermally Persistent % may or may not change. Therefore, the Relative Prolongation Ability Score or total Persistent % subdermally over that of total Persistent % subcutaneously, will be different and very specific for the particular skin affected by Primary Immunodeficiency. However, they are valuable indicators that will help us modify the GAMMAGARD dosage and duration to inject into that "unknown" subdermal space for Aim 2.
Aim 2 would require 12 months, using GAMMAGARD, instead of Gadolinium, to demonstrate the advantages of ASIS device subdermally over subcutaneously, for the same Primary Immunodeficiency subjects. Of course that Relative Prolongation Ability Score in Aim1 will be valuable, but it isn't absolutely required to start Aim 2, because GAMMAGARD's Pharmacokinetics will be studied anyway, by following Peak and Trough levels of immunoglobulin G.
However, the Pharmacokinetics of subdermally injected GAMMAGARD will be just dependent on GAMMAGARD's diffusion out of that subdermal bloodless space; therefore, if GAMMAGARD getting into the bloodstream becomes so severely inhibited, then we can just change the osmolality of GAMMAGARD in the end. The therapeutic advantages of GAMMAGARD with ASIS device subdermally over subcutaneously will also be studied by comparing the reduction of Validated Acute Serious Bacterial Infections, adverse reactions, and injection site pain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gadolinium For abdomen
Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.
Gadolinium Magnevist® (gadopentetate dimeglumine)
1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Gadolinium For abdomen
Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium For abdomen
Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium For abdomen
Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Gadolinium For lower back
Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For lower back
Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Gadolinium For lower back
Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
Gadolinium For lower back
1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score.
Gadolinium For abdomen
Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium For abdomen
Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium For abdomen
Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Gadolinium For lower back
Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For lower back
Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Gadolinium For lower back
Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
subjects (%) of any infections
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Annual rate of any infections
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
subjects (%) with Antibiotic use
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Annual rate with Antibiotic use
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
subjects (%) with Days out of work
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Annual rate with Days out of work
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
(%) with hospitalized infections
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Annual rate hospitalized infections
Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Adverse Injection Local Reactions
Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Headache
Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Fever
Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Nausea
Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Vomiting
Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Fatigue
Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Diarrhea
Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Asthma
Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Oropharyngeal
Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions Abdominal Pain
Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gadolinium For abdomen
Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium For abdomen
Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium For abdomen
Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Gadolinium For lower back
Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For lower back
Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Gadolinium For lower back
Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Efficacy of Gammagard subcutaneously at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subcutaneously at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Efficacy of Gammagard subdermally at Week 12
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Efficacy of Gammagard subdermally at Week 12
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Efficacy of Gammagard subdermally at Week 24
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 24
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Efficacy of Gammagard subdermally at Week 36
subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Efficacy of Gammagard subdermally at Week 36
Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 24
Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subcutaneously at Week 36
Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 12
Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Adverse Reactions of Gammagard subdermally at Week 24
Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Adverse Reactions of Gammagard subdermally at Week 36
Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Genders Eligible for Study: Both
* Accepts Healthy Volunteers: Yes
* Must be outpatient, male or female, of any race, between 18 and 65 years of age.
* Must be able to understand the requirements of the study including maintaining a diary, and sign informed consent.
* Must be in good general health as determined by investigator.
* If female of childbearing potential, must have negative pregnancy test result at screening visit and practice reliable method of contraception
* Patients 12 years or older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies1,2.
Exclusion Criteria
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ASIS Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Nguyen, MD
Role: PRINCIPAL_INVESTIGATOR
AUTOMATIC SUBDERMAL INJECTOR SYSTEM INC
Thanh Phung, MD
Role: PRINCIPAL_INVESTIGATOR
AUTOMATIC SUBDERMAL INJECTOR SYSTEM, INC
Hanh Nguyen, MD
Role: PRINCIPAL_INVESTIGATOR
AUTOMATIC SUBDERMAL INJECTOR SYSTEM,INC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Automatic Subdermal Injector System, Inc
Westminster, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Paonessa DF, Goldstein JC. Anatomy and physiology of head and neck infections (with emphasis on the fascia of the face and neck). Otolaryngol Clin North Am. 1976 Oct;9(3):561-80. No abstract available.
Magnevist (gadopentetate dimeglumine) Injection Product Information: http://pharma.bayer.com/scripts/pages/en/products/diagnostic_imaging/index.php
Botox (onabotulinumtoxinA) Product Information: http://www.botoxcosmetic.com/botox_physician_info/Clinical_Information.aspx http://www.clinicaltrials.gov/ct2/show/NCT01313767?term=Botox+pi&rank=1
GAMMAGARD LIQUID Comparison of Intravenous and Subcutaneous Administration in Primary Immunodeficiency Diseases (PID): http://www.clinicaltrials.gov/ct2/show/NCT00546871?term=Gammagard+subcutaneous&rank=5
Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008 Aug;48(8):1598-601. doi: 10.1111/j.1537-2995.2008.01721.x. Epub 2008 May 2.
Mignogna MD, Fortuna G, Ruoppo E, Adamo D, Leuci S, Fedele S. Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat? Am J Clin Dermatol. 2007;8(5):291-9. doi: 10.2165/00128071-200708050-00004.
Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion. 2003 Aug;43(8):1023-8. doi: 10.1046/j.1537-2995.2003.00496.x.
Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M; Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006 May;26(3):265-73. doi: 10.1007/s10875-006-9021-7.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, Granert C, Haag S, Hernandez D, Kiessling P, Kus J, Pons J, Niehues T, Schmidt S, Schulze I, Borte M. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. J Clin Immunol. 2006 Mar;26(2):177-85. doi: 10.1007/s10875-006-9002-x. Epub 2006 Apr 26.
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl):S525-53. doi: 10.1016/j.jaci.2006.01.015.
Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005 May;94(5 Suppl 1):S1-63. doi: 10.1016/s1081-1206(10)61142-8. No abstract available.
Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009 Dec;4(12):1993-7. doi: 10.2215/CJN.04540709. Epub 2009 Oct 15.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study ASIS for GAMMAGARD in Primary Immunodeficiency
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1R01EB017805
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
NCTEB017805
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.